Madison Clarke
The Stamaril vaccine for yellow fever was developed and manufactured by Sanofi Pasteur, a global leader in vaccine production and a subsidiary of the multinational pharmaceutical company Sanofi. Stamaril, approved by the World Health Organization (WHO) and regulatory authorities in numerous countries, is a live-attenuated vaccine derived from the 17D strain of the yellow fever virus. It has been widely used since its introduction in the 1980s to prevent yellow fever, a potentially fatal viral disease transmitted by infected mosquitoes, primarily in endemic regions of Africa and South America. Sanofi Pasteur's expertise in vaccine development and distribution has played a crucial role in global efforts to control and prevent yellow fever outbreaks.
| Characteristics | Values |
|---|---|
| Manufacturer | Sanofi Pasteur |
| Brand Name | Stamaril |
| Vaccine Type | Live, attenuated viral vaccine |
| Disease Targeted | Yellow Fever |
| Approval Year (FDA) | 2007 (Note: Originally approved in Europe in the 1980s) |
| Dosage | 0.5 mL (subcutaneous injection) |
| Age Indication | Adults and children ≥ 9 months |
| Efficacy | ≥ 95% seroprotection after a single dose |
| Duration of Protection | Lifelong immunity after a single dose (WHO recommendation) |
| Storage Temperature | 2°C to 8°C (refrigerated) |
| Shelf Life | 36 months (unopened vial) |
| Administration | Single dose for most travelers; booster may be required in specific cases |
| Side Effects | Mild (headache, muscle pain, low-grade fever) to rare (severe allergic reactions, YEL-AVD) |
| Contraindications | Severe egg allergy, immunocompromised individuals, infants < 6 months |
| Global Usage | Widely used in endemic regions and for international travelers |
| WHO Prequalification | Yes |
| Production Status | Active (as of latest data) |
Explore related products
![International Certificate of Vaccination with Vinyl Document Holder - World Health Organization Bilingual Version [cards] World Health Organization [Jan 01, 2007]](https://m.media-amazon.com/images/I/61SHjBP1VYL._AC_UY218_.jpg)
What You'll Learn
- Manufacturer: Sanofi Pasteur developed and produced the Stamaril yellow fever vaccine
- Approval: Stamaril was approved by the WHO and EMA for global use
- Composition: Contains live, attenuated yellow fever virus strain 17D
- Distribution: Widely distributed in Europe, Canada, and Australia for travelers
- Effectiveness: Provides long-lasting immunity with a single dose in most cases
Manufacturer: Sanofi Pasteur developed and produced the Stamaril yellow fever vaccine
Sanofi Pasteur, a global leader in vaccine development, stands as the manufacturer behind the Stamaril vaccine, a crucial tool in the fight against yellow fever. This live-attenuated vaccine is designed to protect travelers and residents of endemic areas from the potentially fatal disease. The company's expertise in vaccinology has led to the creation of a product that meets stringent international standards, ensuring safety and efficacy for those at risk.
The development of Stamaril involved rigorous research and clinical trials, demonstrating Sanofi Pasteur's commitment to public health. Administered as a single 0.5 mL dose, the vaccine is recommended for individuals aged 9 months and older, particularly those traveling to or residing in yellow fever-endemic regions. It is essential to receive the vaccination at least 10 days before potential exposure to allow for the development of immunity. Travelers should consult with healthcare providers or specialized travel clinics to ensure compliance with local regulations and to obtain the necessary certification, often referred to as the International Certificate of Vaccination or Prophylaxis (ICVP).
One of the standout features of Stamaril is its long-lasting immunity, with studies indicating protection for at least 30–35 years, and possibly for life, after a single dose. This makes it a highly effective and convenient option for long-term travelers and expatriates. However, certain precautions must be observed. Pregnant women, individuals with severe egg allergies, and those with weakened immune systems should avoid the vaccine unless the benefits outweigh the risks. Healthcare providers play a critical role in assessing eligibility and providing personalized advice.
Comparatively, Stamaril is one of the few yellow fever vaccines approved by the World Health Organization (WHO) and is widely used in international immunization programs. Its production by Sanofi Pasteur ensures a reliable supply chain, addressing global demand effectively. The vaccine’s success underscores the importance of investing in research and development to combat infectious diseases. For those planning travel to high-risk areas, verifying the availability of Stamaril and scheduling vaccination well in advance is a practical step toward ensuring a safe journey.
In conclusion, Sanofi Pasteur’s Stamaril vaccine represents a significant advancement in yellow fever prevention, offering robust protection with a single dose. Its development highlights the company’s role in global health initiatives, providing a vital resource for millions at risk. By understanding its usage, precautions, and benefits, individuals can make informed decisions to safeguard their health while traveling or living in endemic regions.
Does Tricare for Life Cover Shingrix Vaccine Costs?
You may want to see also
Explore related products
Approval: Stamaril was approved by the WHO and EMA for global use
The Stamaril vaccine, a crucial tool in the fight against yellow fever, underwent rigorous evaluation before its global approval. This live-attenuated vaccine, developed by Sanofi Pasteur, garnered the endorsement of two of the world's most respected health authorities: the World Health Organization (WHO) and the European Medicines Agency (EMA). Their stamp of approval signifies a meticulous assessment of Stamaril's safety, efficacy, and quality, paving the way for its widespread use in protecting populations from this potentially fatal disease.
The WHO's prequalification program, a stringent process ensuring vaccines meet international standards, played a pivotal role in Stamaril's global acceptance. This approval allows the vaccine to be procured by United Nations agencies and Gavi, the Vaccine Alliance, facilitating its distribution to countries where yellow fever poses a significant threat. Similarly, the EMA's authorization within the European Union (EU) guarantees its availability for travelers and residents in endemic regions.
Understanding the approval process highlights the vaccine's suitability for diverse populations. Stamaril is administered as a single 0.5 mL subcutaneous injection, offering long-lasting immunity. It's recommended for individuals aged 9 months and older traveling to or residing in yellow fever endemic areas. However, pregnant women, individuals with severe egg allergies, and those with weakened immune systems should consult a healthcare professional before vaccination.
The WHO and EMA approvals not only validate Stamaril's effectiveness but also underscore the importance of global collaboration in combating infectious diseases. By ensuring access to this vital vaccine, these organizations contribute significantly to preventing yellow fever outbreaks and safeguarding public health worldwide.
Understanding Immunosuppression: How It Impacts Vaccine Effectiveness and Safety
You may want to see also
Explore related products
Composition: Contains live, attenuated yellow fever virus strain 17D
The Stamaril vaccine, a critical tool in the fight against yellow fever, owes its efficacy to a specific component: the live, attenuated yellow fever virus strain 17D. This strain is the cornerstone of the vaccine’s ability to confer immunity without causing the disease itself. Developed through decades of scientific refinement, strain 17D represents a triumph of virology, transforming a deadly pathogen into a protective agent. Its inclusion in Stamaril ensures that the vaccine not only stimulates a robust immune response but also maintains a high safety profile, making it suitable for widespread use in endemic regions and among travelers.
Attenuation, the process of weakening a virus while preserving its immunogenic properties, is what makes strain 17D unique. This live but weakened virus replicates in the body just enough to trigger the immune system into producing antibodies and memory cells, preparing it to recognize and combat the actual yellow fever virus. Unlike inactivated vaccines, which often require adjuvants or booster doses, a single 0.5 mL dose of Stamaril, administered subcutaneously, typically confers lifelong immunity in individuals aged 9 months and older. This efficiency is particularly vital in outbreak scenarios, where rapid immunization is essential to curb disease spread.
For travelers and healthcare providers, understanding the composition of Stamaril is crucial for informed decision-making. The live nature of the vaccine means it is contraindicated in certain populations, such as pregnant women, individuals with severe egg allergies, and those with compromised immune systems. However, for eligible recipients, the benefits far outweigh the risks. Practical tips include scheduling vaccination at least 10 days before travel to ensure immunity takes effect and verifying the vaccine’s availability at certified yellow fever vaccination centers, as it requires specialized storage and handling.
Comparatively, strain 17D’s success in Stamaril highlights the broader potential of live, attenuated vaccines in disease prevention. Its development, rooted in Max Theiler’s groundbreaking work in the 1930s, has set a precedent for vaccines against other viral diseases, such as measles and mumps. Theiler’s 17D strain, now manufactured by Sanofi Pasteur, remains the only yellow fever vaccine strain in use globally, a testament to its unparalleled safety and efficacy. This historical context underscores the vaccine’s role not just as a medical product but as a legacy of scientific innovation.
In conclusion, the inclusion of live, attenuated yellow fever virus strain 17D in Stamaril is both a scientific achievement and a practical solution to a persistent public health challenge. Its composition exemplifies the delicate balance between viral activity and immune stimulation, offering protection with minimal risk. For those in endemic areas or planning travel to such regions, Stamaril is more than a vaccine—it’s a shield against a disease that continues to threaten millions. Understanding its composition empowers individuals to make informed choices, ensuring safer journeys and healthier communities.
Join the J&J Vaccine Trial: Your Step-by-Step Sign-Up Guide
You may want to see also
Explore related products
$12.74 $18.99
Distribution: Widely distributed in Europe, Canada, and Australia for travelers
The Stamaril vaccine, manufactured by Sanofi Pasteur, is a critical tool for travelers heading to yellow fever-endemic regions. Its distribution network is strategically designed to cater to the needs of globetrotters, particularly in Europe, Canada, and Australia. In these regions, the vaccine is readily available through designated yellow fever vaccination centers, ensuring that international travelers can access it conveniently. This widespread availability is a testament to the collaborative efforts between Sanofi Pasteur and local health authorities, who recognize the importance of protecting travelers from this potentially fatal disease.
For travelers, obtaining the Stamaril vaccine involves a straightforward process. In Europe, Canada, and Australia, individuals can visit accredited travel clinics or healthcare facilities that stock the vaccine. A single dose of 0.5 mL is administered subcutaneously or intramuscularly, providing immunity for at least 10 years, and possibly for life, according to the World Health Organization (WHO). It is recommended that travelers receive the vaccine at least 10 days before their trip to ensure adequate protection, as this allows sufficient time for the immune system to respond. Notably, the vaccine is approved for use in individuals aged 9 months and older, making it suitable for most travelers, including children.
One of the key advantages of Stamaril's distribution network is its adaptability to the unique needs of each region. In Europe, for instance, the vaccine is often available through national immunization programs, ensuring that travelers can access it through their local healthcare providers. In Canada, the Public Health Agency of Canada maintains a list of designated yellow fever vaccination centers, streamlining the process for travelers. Similarly, in Australia, the vaccine is accessible through travel medicine specialists and select general practices, catering to the country's high volume of outbound travelers. This localized approach ensures that travelers can obtain the vaccine efficiently, regardless of their location.
Despite its widespread availability, travelers should be aware of certain considerations when seeking the Stamaril vaccine. For instance, pregnant women, individuals with severe egg allergies, and those with compromised immune systems may require special evaluation before receiving the vaccine. Additionally, travelers should carry their International Certificate of Vaccination or Prophylaxis (ICVP), also known as the "yellow card," as proof of vaccination, which may be required for entry into certain countries. By understanding these nuances and planning ahead, travelers can ensure a smooth vaccination process and focus on enjoying their journey, protected from the threat of yellow fever.
In conclusion, the distribution of the Stamaril vaccine in Europe, Canada, and Australia is a well-coordinated effort that prioritizes the needs of travelers. With its widespread availability, clear administration guidelines, and localized support, the vaccine plays a vital role in safeguarding global travelers from yellow fever. As international travel continues to rebound, the importance of accessible and reliable vaccination services cannot be overstated, making Stamaril an indispensable tool for modern adventurers.
Is It Illegal to Skip Childhood Vaccinations in the UK?
You may want to see also
Explore related products
Effectiveness: Provides long-lasting immunity with a single dose in most cases
The Stamaril vaccine, developed by Sanofi Pasteur, stands out in the realm of yellow fever prevention due to its remarkable efficacy. A single dose of 0.5 mL, administered subcutaneously or intramuscularly, typically confers lifelong immunity in most individuals. This is a significant advantage over other vaccines that may require boosters or multiple doses to maintain protection. For travelers and residents in endemic areas, this means a one-time intervention can provide decades of defense against a potentially fatal disease.
Clinical trials and real-world data underscore Stamaril’s effectiveness. Studies show that 95% of recipients develop protective antibodies within 10 to 30 days post-vaccination. Even more striking, seroconversion rates remain high across diverse age groups, from children as young as 9 months to adults over 60. However, it’s important to note that individuals with weakened immune systems, such as those with HIV or undergoing chemotherapy, may exhibit lower immune responses. In such cases, consulting a healthcare provider for personalized advice is crucial.
The vaccine’s long-lasting immunity is particularly beneficial for travelers visiting yellow fever-endemic regions. Unlike vaccines like influenza, which require annual updates, Stamaril’s single-dose regimen simplifies preparation for international trips. For instance, a traveler planning a safari in sub-Saharan Africa can receive the vaccine at least 10 days before departure, ensuring immunity throughout their journey. This convenience, coupled with its high efficacy, has made Stamaril a cornerstone of global yellow fever prevention strategies.
Despite its effectiveness, certain precautions must be observed. The vaccine is contraindicated in individuals with severe egg allergies, as it is produced using chicken eggs. Additionally, pregnant women and those with thymus disorders should avoid vaccination unless the benefits outweigh the risks. For children under 6 months, the vaccine is not recommended due to safety concerns. These exceptions highlight the importance of individualized assessment by healthcare professionals before administration.
In summary, Stamaril’s ability to provide long-lasting immunity with a single dose makes it a highly effective tool in combating yellow fever. Its broad applicability, from infants to the elderly, coupled with its convenience, positions it as a vital resource for both public health and personal protection. By understanding its strengths and limitations, individuals can make informed decisions to safeguard themselves against this dangerous disease.
When Should Kids Get Their First MMR Vaccine?
You may want to see also
Frequently asked questions
The Stamaril vaccine was developed by Sanofi Pasteur, a global pharmaceutical company specializing in vaccines.
No, Stamaril is one of the vaccines approved for yellow fever, but other vaccines like YF-Vax (manufactured by Sanofi Pasteur in the U.S.) are also used in different regions.
Stamaril was first approved for use in Europe in 1986 and has since been widely used globally for yellow fever prevention.
Stamaril is primarily used in Europe, Canada, Australia, and other regions outside the United States, as YF-Vax is the approved vaccine in the U.S.
The Stamaril vaccine is highly effective, providing long-lasting immunity against yellow fever in over 95% of recipients after a single dose.
